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ABSTRACT
We have performed exome-wide association studies to identify single nucleotide 
polymorphisms that influence serum concentrations of triglycerides, high density 
lipoprotein (HDL)–cholesterol, or low density lipoprotein (LDL)–cholesterol or 
confer susceptibility to hypertriglyceridemia, hypo–HDL-cholesterolemia, or hyper–
LDL-cholesterolemia in Japanese. Exome-wide association studies for serum 
triglycerides (13,414 subjects), HDL-cholesterol (14,119 subjects), LDL-cholesterol 
(13,577 subjects), hypertriglyceridemia (4742 cases, 8672 controls), hypo–HDL-
cholesterolemia (2646 cases, 11,473 controls), and hyper–LDL-cholesterolemia (4489 
cases, 9088 controls) were performed with HumanExome-12 DNA Analysis BeadChip 
or Infinium Exome-24 BeadChip arrays. Twenty-four, 69, or 32 loci were significantly  
(P < 1.21 × 10–6) associated with serum triglycerides, HDL-cholesterol, or LDL-
cholesterol, respectively, with 13, 16, or 9 of these loci having previously been associated 
with triglyceride-, HDL-cholesterol–, or LDL-cholesterol–related traits, respectively. 
Two single nucleotide polymorphisms (rs10790162, rs7350481) were significantly 
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INTRODUCTION
Dyslipidemia, including hypertriglyceridemia, hypo–
high density lipoprotein (HDL)–cholesterolemia, and 
hyper–low density lipoprotein (LDL)–cholesterolemia, is a 
multifactorial disorder that results from an interaction between 
genetic background and environmental factors [1, 2]. Given 
that dyslipidemia is an important risk factor for coronary 
artery disease, ischemic stroke [3], and colorectal cancer [4], 
its personalized prevention is an important public health goal.
Genome-wide association studies (GWASs) 
[5–8] and gene-centric meta-analysis [9] have implicated 
various genes and loci as determinants of blood lipid levels 
or in predisposition to dyslipidemia in European-ancestry 
populations. Genetic variants associated with lipid profiles 
have been extensively investigated, with one recent study 
identifying 157 such loci, including 62 variants not previously 
reported [10]. Recent GWASs [11, 12] or studies based on 
exome [13] or whole-genome [14] sequencing in European-
ancestry populations also identified low-frequency or rare 
variants related to circulating lipid levels. Although several 
polymorphisms have been shown to be related to blood lipid 
profiles in the Japanese population [15], genetic variants—
including low-frequency or rare variants—that influence 
circulating lipid levels or contribute to genetic susceptibility to 
dyslipidemia in Japanese remain to be identified definitively.
We have now performed exome-wide association 
studies (EWASs) to identify single nucleotide 
polymorphisms (SNPs)—in particular, low-frequency 
or rare coding variants with moderate to large effect 
sizes—that influence the serum concentrations of 
triglycerides, HDL-cholesterol, or LDL-cholesterol or 
confer susceptibility to dyslipidemia in Japanese. We used 
Illumina arrays that provide coverage of functional SNPs 
in entire exons including such variants.
RESULTS
EWASs for serum concentrations of triglycerides, 
HDL-cholesterol, or LDL-cholesterol
We applied linear regression analysis to examine 
the relation of genotypes for 41,371 SNPs to the serum 
triglyceride concentration in 13,414 subjects, for 41,225 
SNPs to the serum HDL-cholesterol concentration in 
14,119 subjects, or for 41,347 SNPs to the serum LDL-
cholesterol concentration in 13,577 subjects. Manhattan 
plots for the EWASs are shown in Supplementary Figure 
1. After Bonferroni’s correction, 46, 104, or 40 SNPs were 
significantly (P < 1.21 × 10–6) associated with the serum 
concentrations of triglycerides (Table 1), HDL-cholesterol 
(Supplementary Table 1), or LDL-cholesterol (Table 2), 
respectively.
EWASs for hypertriglyceridemia, hypo–HDL-
cholesterolemia, or hyper–LDL-cholesterolemia
We performed the EWAS for hypertriglyceridemia 
with 13,414 subjects (4742 cases, 8672 controls), that 
for hypo–HDL-cholesterolemia with 14,119 subjects 
(2646 cases, 11,473 controls), and that for hyper–LDL-
cholesterolemia with 13,577 subjects (4489 cases, 9088 
controls). Characteristics of the subjects are shown 
in Table 3. In the study of hypertriglyceridemia, age, 
the frequency of men, body mass index (BMI), and the 
prevalence of smoking, hypertension, diabetes mellitus, 
chronic kidney disease, and hyperuricemia as well as 
the serum concentrations of triglycerides and LDL-
cholesterol and the ratio of LDL-cholesterol to HDL-
cholesterol were greater, whereas the serum concentration 
of HDL-cholesterol was lower, in subjects with 
hypertriglyceridemia than in controls. In the study of hypo–
HDL-cholesterolemia, age, the frequency of men, BMI, 
and the prevalence of smoking, hypertension, diabetes 
mellitus, chronic kidney disease, and hyperuricemia as 
well as the serum concentration of triglycerides and the 
ratio of LDL-cholesterol to HDL-cholesterol were greater, 
whereas the serum concentration of HDL-cholesterol was 
lower, in subjects with hypo–HDL-cholesterolemia than 
in controls. In the study of hyper–LDL-cholesterolemia, 
BMI, the prevalence of smoking, the serum concentrations 
of triglycerides and LDL-cholesterol, and the ratio of LDL-
cholesterol to HDL-cholesterol were greater, whereas age, 
the prevalence of chronic kidney disease, and the serum 
concentration of HDL-cholesterol were lower, in subjects 
with hyper–LDL-cholesterolemia than in controls.
related to both serum triglycerides and hypertriglyceridemia; three polymorphisms 
(rs146515657, rs147317864, rs12229654) were significantly related to both serum 
HDL-cholesterol and hypo–HDL-cholesterolemia; and six polymorphisms (rs2853969, 
rs7771335, rs2071653, rs2269704, rs2269703, rs2269702) were significantly related 
to both serum LDL-cholesterol and hyper–LDL-cholesterolemia. Among polymorphisms 
identified in the present study, two polymorphisms (rs146515657, rs147317864) 
may be novel determinants of hypo–HDL-cholesterolemia, and six polymorphisms 
(rs2853969, rs7771335, rs2071653, rs2269704, rs2269703, rs2269702) may 
be new determinants of hyper–LDL-cholesterolemia. In addition, 12, 61, 23, or 3 
polymorphisms may be new determinants of the serum triglyceride, HDL-cholesterol, 
or LDL-cholesterol concentrations or of hyper–LDL-cholesterolemia, respectively.
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Table 1: The 46 SNPs significantly (P < 1.21 × 10–6) associated with serum triglyceride concentration 
in the EWAS
Gene dbSNP Nucleotide 
(amino acid) 
substitutiona
Chromosome: 
position
MAF (%) P
(genotype)
APOA5 rs2075291 C/A (G185C) 11: 116790676 7.3 2.98 × 10–65
rs7350481 C/T 11: 116715567 27.7 3.10 × 10–38
APOA5 rs2266788 T/C 11: 116789970 26.2 1.03 × 10–35
BUD13 rs10790162 G/A 11: 116768388 26.3 1.11 × 10–35
ZPR1 rs964184 C/G 11: 116778201 26.3 2.17 × 10–35
rs9326246 G/C 11: 116741017 26.5 6.24 × 10–34
ZPR1 rs2075290 T/C 11: 116782580 26.7 4.87 × 10–33
MTFR2 rs143974258 G/A (R360*) 6: 136231355 3.3 2.10 × 10–19
APOA4 rs5104 T/C (N147S) 11: 116821618 35.7 3.57 × 10–14
C21orf59 rs76974938 C/T (D67N) 21: 32609946 2.4 4.74 × 10–14
LPL rs328 C/G (S474*) 8: 19962213 12.9 8.93 × 10–13
rs10096633 C/T 8: 19973410 12.7 1.25 × 10–12
rs17482753 G/T 8: 19975135 12.6 1.25 × 10–12
rs12678919 A/G 8: 19986711 12.6 1.36 × 10–12
rs10503669 C/A 8: 19990179 12.6 1.40 × 10–12
SIK3 rs2075292 G/T 11: 116861796 42.7 1.58 × 10–12
GCKR rs1260326 T/C (L446P) 2: 27508073 43.6 1.62 × 10–12
SIK3 rs10047462 G/T 11: 116851325 47.6 1.78 × 10–12
GCKR rs780093 A/G 2: 27519736 43.0 8.98 × 10–12
rs1260333 T/C 2: 27525757 42.9 1.11 × 10–11
rs7016880 G/C 8: 20019235 12.0 2.64 × 10–11
TNC rs138406927 C/T (A1096T) 9: 115064848 2.1 2.66 × 10–10
LAIR2 rs34429135 T/A (F115Y) 19: 54508164 2.5 1.24 × 10–9
PAFAH1B2 rs7112513 G/A 11: 117166645 45.3 2.21 × 10–9
PAFAH1B2 rs4936367 A/G (V151M) 11: 117166645 45.3 2.24 × 10–9
rs12269901 G/C 11: 117103213 36.6 2.33 × 10–9
C2orf16 rs1919128 G/A (V774I) 2: 27578892 42.2 2.45 × 10–9
OR4F6 rs141569282 G/A (A117T) 15: 101806068 1.7 8.08 × 10–9
rs2954038 A/C 8: 125495147 30.3 1.20 × 10–8
rs2197089 C/T 8: 19968862 27.6 3.31 × 10–8
C2orf16 rs1919127 C/T (A685V) 2: 27578626 42.2 4.30 × 10–8
LOC101929011 rs1240773 G/T 11: 116649810 29.0 5.77 × 10–8
LPL rs15285 G/A 8: 19967156 19.2 6.16× 10–8
LPL rs13702 A/G 8: 19966981 19.2 6.17 × 10–8
rs2954026 G/T 8: 125472284 33.1 8.37 × 10–8
LPL rs326 A/G 8: 19961928 19.4 8.74 × 10–8
COL6A5 rs200982668 G/A (E2501K) 3: 130470894 1.3 8.94 × 10–8
rs1264429 A/G 6: 30597324 13.4 9.04 × 10–8
rs1441756 T/G 8: 20010875 19.0 1.29 × 10–7
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We applied Fisher’s exact test to examine 
the relation of allele frequencies of 41,371 SNPs to 
hypertriglyceridemia, of 41,225 SNPs to hypo–HDL-
cholesterolemia, or of 41,347 SNPs to hyper–LDL-
cholesterolemia. Manhattan plots for the EWASs are 
shown in Supplementary Figure 2. After Bonferroni’s 
correction, 73, 87, or 114 SNPs were significantly 
(P < 1.21 × 10–6) associated with hypertriglyceridemia 
(Supplementary Table 2), hypo–HDL-cholesterolemia 
(Supplementary Table 3), or hyper–LDL-cholesterolemia 
(Supplementary Table 4), respectively. The genotype 
distributions of these SNPs were in Hardy-Weinberg 
equilibrium (P > 0.001) among the corresponding controls 
for hypertriglyceridemia (Supplementary Table 5), hypo–
HDL-cholesterolemia (Supplementary Table 6), or hyper–
LDL-cholesterolemia (Supplementary Table 7).
Multivariable logistic regression analysis 
of hypertriglyceridemia, hypo–HDL-
cholesterolemia, or hyper–LDL-cholesterolemia
The relation of the 73, 87, or 114 SNPs identified by 
the EWASs for dyslipidemia to hypertriglyceridemia, hypo–
HDL-cholesterolemia, and hyper–LDL-cholesterolemia, 
respectively, was examined further by multivariable logistic 
regression analysis with adjustment for age and sex. Two 
SNPs—rs10790162 (G/A) of BUD13 and rs7350481 
(C/T) at 11q23.3—were significantly [P < 1.71 × 10–4 
(0.05/292)] associated with hypertriglyceridemia (Table 
4, Supplementary Table 8); three SNPs—rs146515657 
[T/C (N650S)] of USP4, rs147317864 [C/T (A262T)] 
of TRABD2B, and rs12229654 (T/G) at 12q24.1—were 
significantly [P < 1.44 × 10–4 (0.05/348)] associated with 
hypo–HDL-cholesterolemia (Table 4, Supplementary 
Table 9); and nine SNPs—rs7771335 (A/G) at 6p22.1, 
rs76974938 [C/T (D67N)] of C21orf59, rs2071653 (C/T) 
of MOG, rs2853969 (C/T) at 6p21.3, rs2269704 (C/T) of 
PPP1R18, rs2269703 (G/A) of NRM, rs495089 (T/C) at 
6p21.3, rs2269702 (A/G) of MDC1, and rs1233399 (C/T) 
at 6p22.1—were significantly [P < 1.10 × 10–4 (0.05/456)] 
associated with hyper–LDL-cholesterolemia (Table 4, 
Supplementary Table 10).
Linkage disequilibrium and haplotype analysis
Given that eight SNPs (rs7771335, rs2071653, 
rs2853969, rs2269704, rs2269703, rs495089, rs2269702, 
rs1233399) associated with hyper–LDL-cholesterolemia 
were all located at chromosome 6p22.1-p21.3, we 
examined linkage disequilibrium among these SNPs 
as well as the relation of their haplotypes to this 
condition. The eight SNPs were all in strong linkage 
disequilibrium (Supplementary Table 11). Haplotype 
analysis revealed that the haplotypes A (rs7771335)–C 
(rs2071653)–C (rs2853969)–C (rs2269704)–G 
(rs2269703)–T (rs495089)–A (rs2269702)–T (rs1233399) 
and G (rs7771335)–T (rs2071653)–T (rs2853969)–T 
(rs2269704)–A (rs2269703)–C (rs495089)–G (rs2269702)–C 
(rs1233399) were significantly (P < 4.31 × 10–4) associated 
with hyper–LDL-cholesterolemia, with the former haplotype 
being protective against and the latter representing a risk 
factor for this condition (Supplementary Table 12).
Relation of identified SNPs to serum triglyceride, 
HDL-cholesterol, or LDL-cholesterol levels
We examined the relation of genotypes of identified 
SNPs to serum triglyceride, HDL-cholesterol, or LDL-
cholesterol levels by one-way analysis of variance. The 
46 SNPs identified in the EWAS for serum triglyceride 
concentration, including the two SNPs also found to be 
associated with hypertriglyceridemia (rs10790162 of 
BUD13, rs7350481 at 11q23.3), were all significantly [P 
< 0.0011 (0.05/46)] associated with serum triglyceride 
level (Supplementary Table 13). The 104 SNPs identified 
in the EWAS for serum HDL-cholesterol concentration, 
including two of the three SNPs found to be associated 
with hypo–HDL-cholesterolemia (rs146515657 of USP4, 
rs12229654 at 12q24.1), were all significantly [P < 
4.76 × 10–4(0.05/105)] associated with the serum HDL-
cholesterol level, as was the SNP associated with hypo–
HDL-cholesterolemia alone (rs147317864 of TRABD2B) 
(Supplementary Table 14). The 40 SNPs identified in 
the EWAS for serum LDL-cholesterol concentration, 
including one SNP also found to be associated with 
rs2083637 T/C 8: 20007664 19.0 1.53 × 10–7
rs2954033 G/A 8: 125481504 33.3 1.55 × 10–7
LPL rs301 T/C 8: 19959423 19.3 1.62× 10–7
MUC17 rs78010183 A/T (T1305S) 7: 101035329 1.8 5.96 × 10–7
MARCH1 rs61734696 G/T (Q137K) 4: 164197303 1.2 7.44 × 10–7
rs4938303 T/C 11: 116714271 43.0 8.13 × 10–7
MRVI1 rs4909945 C/T (V11I) 11: 10652192 0.3 1.03× 10–6
The relation of genotypes of SNPs to the serum concentration of triglycerides was examined by linear regression analysis. 
aMajor allele/minor allele.
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Table 2: The 40 SNPs significantly (P < 1.21 × 10–6) associated with serum LDL-cholesterol 
concentration in the EWAS
Gene dbSNP Nucleotide (amino 
acid) substitutiona
Chromosome:
position
MAF (%) P (genotype)
APOE rs7412 C/T (R176C) 19: 44908822 4.3 6.42 × 10–51
APOC1 rs445925 C/T 19: 44912383 6.6 4.19 × 10–18
APOB rs13306206 G/A (P955S) 2: 21019859 3.2 3.34 × 10–16
PCSK9 rs151193009 C/T (R93C) 1: 55043912 1.1 3.35 × 10–14
APOE rs769449 G/A 19: 44906745 7.7 3.58 × 10–11
PSRC1 rs599839 A/G 1: 109279544 7.9 1.51 × 10–10
CELSR2 rs629301 A/C 1: 109275684 7.8 1.96 × 10–10
APOB rs13306194 G/A (R532W) 2: 21029662 12.1 3.05 × 10–10
CELSR2 rs12740374 G/T 1: 109274968 7.7 4.45 × 10–10
rs602633 C/A 1: 109278889 7.6 4.80 × 10–10
CELSR2 rs646776 A/G 1: 109275908 7.7 4.98× 10–10
ABO rs1053878 G/A (P156L) 9: 133256264 22.8 1.63 × 10–9
rs651007 G/A 9: 133278431 27.9 1.12 × 10–8
rs579459 T/C 9: 133278724 27.9 1.18 × 10–8
rs635634 G/A 9: 133279427 27.8 1.28 × 10–8
rs507666 G/A 9: 136149399 27.8 1.36 × 10–8
MUC22 rs117024916 A/G (T71A) 6: 31025642 9.9 7.55 × 10–8
VARS rs11751198 G/A 6: 31785749 9.5 1.67 × 10–7
CCHCR1 rs147733073 C/G (H486Q) 6: 31145462 10.2 1.94 × 10–7
rs2853969 C/T 6: 31388797 9.7 2.02 × 10–7
MSH5 rs11754464 C/T 6: 31755958 9.5 2.88 × 10–7
VARS rs5030798 C/T (V1055I) 6: 31779733 9.5 3.60 × 10–7
PRRC2A rs11538264 G/A (V1774M) 6: 31635412 9.5 3.71 × 10–7
FAM65B rs150142878 C/T (R371Q) 6: 24847657 5.6 3.72 × 10–7
HSPA1B rs6457452 C/T 6: 31827773 9.7 3.85 × 10–7
LY6G6C rs117894946 G/C (G75A) 6: 31719250 9.5 4.04 × 10–7
C6orf48 rs11968400 C/T 6: 31836952 9.7 4.13× 10–7
rs12210887 G/T 6: 31847946 9.7 4.61 × 10–7
KIAA0319 rs4576240 G/T (P142T) 6: 24596250 5.5 4.85 × 10–7
rs2596574 G/A 6: 31366397 9.7 5.67 × 10–7
ZSCAN31 rs6922302 C/G (P128A) 6: 28327533 9.6 6.40 × 10–7
NEU1 rs13118 T/A 6: 31859509 9.7 6.46 × 10–7
ZSCAN26 rs76463649 A/G (N15S) 6: 28271963 9.6 6.71 × 10–7
LY6G6F rs17200983 C/A (P34Q) 6: 31707506 9.5 6.89 × 10–7
rs3129029 A/C 6: 29694666 23.0 7.50 × 10–7
LY6G6F rs9267546 G/A 6: 31705659 9.8 9.05 × 10–7
LY6G6F rs9267547 G/A (A107T) 6: 31707724 10.0 9.88 × 10–7
TNXB rs140770834 C/G (L2271V) 6: 32064851 8.8 1.14 × 10–6
TNXB rs11751545 A/C 6: 32073266 8.8 1.14 × 10–6
ABCF1 rs4148249 C/A 6: 30590413 10.1 1.17 × 10–6
The relation of genotypes of SNPs to the serum concentration of LDL-cholesterol was examined by linear regression 
analysis. aMajor allele/minor allele.
Oncotarget38955www.impactjournals.com/oncotarget
hyper–LDL-cholesterolemia (rs2853969 at 6p21.3), were 
all significantly [P < 0.0010 (0.05/48)] associated with 
serum LDL-cholesterol level, as were five of the eight 
SNPs associated with hyper-LDL-cholesterolemia alone 
(rs7771335 at 6p22.1, rs2071653 of MOG, rs2269704 
of PPP1R18, rs2269703 of NRM, rs2269702 of MDC1) 
(Supplementary Table 15).
Relation of SNPs identified in the present study 
to dyslipidemia-related phenotypes examined in 
previous GWASs
We examined the relation of genes, chromosomal 
loci, and SNPs identified in the present study to 
dyslipidemia-related phenotypes included in previous 
GWASs deposited in GWAS Catalog (http://www.
ebi.ac.uk/gwas). Among the 24 loci associated with 
triglyceride-related traits in the present study, 13 loci—
BUD13 [15], 11q23.3 [16], APOA5 [15, 16], ZPR1 
[16], APOA4 [15, 17], LPL [15, 17], 8p21.3 [15, 18], 
SIK3 [19, 20], GCKR [16], 2p23 [17, 21], C2orf16 [22], 
8q24.1 [23], and LOC101929011 [21]—were previously 
shown to be related to the circulating triglyceride level 
or hypertriglyceridemia (Supplementary Table 16). 
Among the 69 loci associated with HDL-cholesterol–
related traits in the present study, 16 loci—12q24.1 
[24], 16q13 [15, 16], CETP [15, 16], APOA5 [16], LIPC 
[16, 17], HECTD4 [24], LILRB2 [8], LPL [15, 16], 
8p21.3 [15, 16], LOC101928635 [10, 17], BUD13 [16], 
ZPR1 [23], ABCA1 [10, 16], 11q23.3 [16], OAS3 [24], 
and CD36 [25]—were previously shown to be related 
to the blood HDL-cholesterol level or hypo–HDL-
cholesterolemia (Supplementary Table 17). Among the 
32 loci associated with LDL-cholesterol–related traits in 
the present study, nine loci—APOE [26], APOC1 [27], 
APOB [16, 17], PCSK9 [17], PSRC1 [12, 28], CELSR2 
[10, 16], 1p13.3 [16], ABO [17], and 9q34.2 [8, 17]—were 
previously shown to be related to the circulating LDL-
cholesterol concentration or hyper–LDL-cholesterolemia 
(Supplementary Table 18).
DISCUSSION
We found that two SNPs—rs10790162 of BUD13 
and rs7350481 at 11q23.3—were significantly related 
to both the serum triglyceride concentration and 
hypertriglyceridemia; three SNPs—rs146515657 of USP4, 
rs147317864 of TRABD2B, and rs12229654 at 12q24.1—
were significantly related to both the serum HDL-
cholesterol concentration and hypo–HDL-cholesterolemia; 
and six SNPs—rs2853969 at 6p21.3, rs7771335 at 
6p22.1, rs2071653 of MOG, rs2269704 of PPP1R18, 
rs2269703 of NRM, and rs2269702 of MDC1—were 
significantly related to both the serum LDL-cholesterol 
concentration and hyper–LDL-cholesterolemia. Among 
these SNPs, rs146515657 of USP4 and rs147317864 of 
TRABD2B may be novel determinants of hypo–HDL-
cholesterolemia, whereas rs2853969 at 6p21.3, rs7771335 
at 6p22.1, rs2071653 of MOG, rs2269704 of PPP1R18, 
rs2269703 of NRM, and rs2269702 of MDC1 may be 
new determinants of hyper–LDL-cholesterolemia. We 
also found that 12, 61, 23, and 3 SNPs may be new 
Table 3: Characteristics of the 14,337 study subjects
Characteristic Hyper 
triglyceridemia
Controls P Hypo–HDL-
cholesterolemia
Controls P Hyper–LDL-
cholesterolemia
Controls P
No. of subjects 4742 8672 2646 11,473 4489 9088
Age (years) 62.0 ± 12.9 59.8 ± 13.8 < 0.0001 65.5 ± 14.1 60.4 ± 13.4 < 0.0001 60.0 ± 12.3 61.0 ± 13.9 < 0.0001
Sex (male/female, %) 67.3/32.7 51.2/48.8 < 0.0001 77.5/22.5 52.0/48.0 < 0.0001 53.6/46.4 57.5/42.5 0.0133
BMI (kg/m2) 24.4 ± 3.5 22.7 ± 3.3 < 0.0001 24.5 ± 3.6 23.0 ± 3.4 < 0.0001 23.6 ± 3.4 23.1 ± 3.5 < 0.0001
Current or former 
smoker (%)
44.9 31.5 < 0.0001 51.3 33.7 < 0.0001 38.5 35.1 0.0002
Hypertension (%) 63.7 47.1 < 0.0001 70.0 50.3 < 0.0001 51.0 53.6 0.0057
Diabetes mellitus (%) 31.8 19.8 < 0.0001 42.9 20.3 < 0.0001 22.0 23.8 0.0224
Chronic kidney 
disease (%)
27.8 21.5 < 0.0001 32.5 22.1 < 0.0001 21.4 24.9 < 0.0001
Hyperuricemia (%) 27.8 12.5 < 0.0001 27.5 15.6 < 0.0001 18.7 16.9 0.0180
Serum triglycerides 
(mmol/L)
2.34 ± 1.23 0.98 ± 0.33 < 0.0001 1.82 ± 1.32 1.37 ± 0.91 < 0.0001 1.52 ± 0.88 1.43 ± 1.10 < 0.0001
Serum HDL-
cholesterol (mmol/L)
1.31 ± 0.37 1.61 ± 0.47 < 0.0001 0.91 ± 0.20 1.62 ± 0.41 < 0.0001 1.50 ± 0.41 1.52 ± 0.48 0.0007
Serum LDL-
cholesterol (mmol/L)
3.29 ± 0.94 3.04 ± 0.79 < 0.0001 3.09 ± 0.96 3.12 ± 0.83 0.2553 3.91 ± 0.77 2.70 ± 0.56 < 0.0001
LDL-cholesterol/
HDL-cholesterol
2.66 ± 1.05 2.06 ± 0.88 < 0.0001 3.37 ± 1.24 2.05 ± 0.76 < 0.0001 2.85 ± 1.11 1.95 ± 0.74 < 0.0001
Quantitative data are means ± SD and were compared between subjects with hypertriglyceridemia, hypo–HDL-cholesterolemia, or hyper–LDL-
cholesterolemia and corresponding controls with the unpaired Student’s t test. Categorical data were compared between two groups with Fisher’s exact test. 
Based on Bonferroni’s correction, a P value of < 0.0014 (0.05/36) was considered statistically significant.
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determinants of the serum triglyceride, HDL-cholesterol, 
or LDL-cholesterol concentrations or of hyper–LDL-
cholesterolemia, respectively.
SNPs associated with serum HDL-cholesterol or 
LDL-cholesterol levels
The ubiquitin specific peptidase 4 gene (USP4) is 
located at chromosome 3p21.31 (NCBI Gene, https://
www.ncbi.nlm.nih.gov/gene) and is expressed in various 
tissues and organs (The Human Protein Atlas, http://www.
proteinatlas.org). Ubiquitin-specific proteases promote 
posttranslational protein modification by reversing 
protein ubiquitination and thereby activates multiple 
biological processes including the cell cycle, DNA repair, 
and intracellular signaling [29]. USP4 accelerates the 
growth, invasion, and metastasis of colorectal cancer 
[29, 30]. We have now shown that rs146515657 [T/C 
(N650S)] of USP4 was significantly associated with both 
the serum HDL-cholesterol concentration and hypo–HDL-
cholesterolemia, with the minor C allele being related to 
a lower serum level of HDL-cholesterol, although the 
molecular mechanism underlying this association remains 
unclear.
The TraB domain containing 2B gene (TRABD2B) 
is located at chromosome 1p33 (NCBI Gene) and is 
expressed ubiquitously (The Human Protein Atlas). 
TRABD2B encodes the metalloprotease TIKI2 that inhibits 
the Wnt/β-catenin signaling by cleavage of the amino 
terminus of Wnt protein [31]. The expression of TIKI2 
was reduced in osteosarcoma specimens and the increased 
expression of TIKI2 inhibited the growth of osteosarcoma 
in vivo, suggesting TIKI2 suppresses the growth of 
osteosarcoma [32]. We have now shown that rs147317864 
[C/T (A262T)] of TRABD2B was significantly associated 
with both the serum concentration of HDL-cholesterol 
and hypo–HDL-cholesterolemia, with the minor T 
allele being related to a reduced level of serum HDL-
cholesterol, although the functional relevance underlying 
this association remains unclear.
The myelin oligodendrocyte glycoprotein gene 
(MOG) is located at chromosome 6p22.1 (NCBI Gene) 
and is highly expressed in brain (The Human Protein 
Atlas). The MOG protein is localized to the outer surface 
of the myelin sheath of neurons in the central nervous 
system and is a key antigen for autoimmune responses 
that result in inflammation and demyelination [33, 34]. 
Both B cell responses and antibodies to MOG have also 
been detected in patients with demyelinating diseases 
such as multiple sclerosis and acute disseminating 
encephalomyelitis [34]. We have now shown that 
rs2071653 (C/T) of MOG was significantly associated 
with both the serum LDL-cholesterol concentration and 
hyper–LDL-cholesterolemia, with the minor T allele being 
related to an increased serum level of LDL-cholesterol, 
although the underlying molecular mechanism remains 
unknown.
The protein phosphatase 1 regulatory subunit 18 
gene (PPP1R18) is located at chromosome 6p21.33 (NCBI 
Gene) and is expressed in various tissues (The Human 
Table 4: Relation of SNPs to hypertriglyceridemia, hypo–HDL-cholesterolemia, or hyper–LDL-
cholesterolemia as determined by multivariable logistic regression analysis
SNP Dominant Recessive Additive 1 Additive 2
P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI)
Hypertriglyceridemia
rs10790162 G/A <1.0 × 10–23 1.48 (1.38–1.59) 1.55 × 10–12 1.62 (1.42–1.85) 5.86 × 10–19 1.41 (1.31–1.53) 5.22 × 10–19 1.87 (1.63–2.15)
rs7350481 C/T <1.0 × 10–23 1.50 (1.40–1.61) 9.45 × 10–11 1.54 (1.35–1.75) 1.62 × 10–21 1.45 (1.34–1.56) 6.31 × 10–18 1.81 (1.58–2.07)
Hypo–HDL-
cholesterolemia
rs146515657 T/C (N650S) <1.0 × 10–23 35.37 (15.61–95.21) ND <1.0 × 10–23 35.37 (15.61–95.21) ND
rs147317864 C/T (A262T) 2.26 × 10–14 1.30 × 109 (ND) ND 2.26 × 10–14 1.30 × 109 (ND) ND
rs12229654 T/G 5.45 × 10–9 1.30 (1.19–1.42) 0.0113 1.28 (1.06–1.53) 9.89 × 10–8 1.29 (1.17–1.41) 0.0005 1.41 (1.16–1.70)
Hyper–LDL-
cholesterolemia
rs7771335 A/G 8.86 × 10–12 1.29 (1.20–1.39) 7.50 × 10–7 1.45 (1.26–1.68) 2.48 × 10–8 1.24 (1.15–1.34) 3.81 × 10–9 1.58 (1.36–1.83)
rs76974938 C/T (D67N) 8.58 × 10–13 0.48 (0.39–0.59) ND 8.58 × 10–13 0.48 (0.39–0.59) ND
rs2071653 C/T 8.58 × 10–9 1.23 (1.15–1.33) 7.00 × 10–8 1.42 (1.25–1.61) 2.20 × 10–5 1.18 (1.09–1.27) 4.26 × 10–10 1.52 (1.34–1.74)
rs2853969 C/T 2.11 × 10–10 1.34 (1.22–1.46) 0.0199 1.45 (1.06–1.96) 2.31 × 10–9 1.33 (1.21–1.45) 0.0080 1.53 (1.12–2.07)
rs2269704 C/T 3.83 × 10–9 1.28 (1.18–1.39) 0.1776 9.70 × 10–9 1.28 (1.18–1.39) 0.0707
rs2269703 G/A 4.42 × 10–9 1.28 (1.18–1.39) 0.1911 1.05 × 10–8 1.28 (1.18–1.39) 0.0773
rs495089 T/C 2.90 × 10–6 1.20 (1.11–1.29) 4.45 × 10–5 1.21 (1.11–1.33) 0.0005 1.15 (1.06–1.25) 1.87 × 10–7 1.32 (1.19–1.46)
rs2269702 A/G 2.74 × 10–7 1.22 (1.13–1.32) 0.0147 1.27 (1.05–1.54) 3.25 × 10–6 1.21 (1.11–1.30) 0.0027 1.35 (1.11–1.63)
rs1233399 C/T 3.11 × 10–6 0.84 (0.78–0.90) 0.0063 0.81 (0.69–0.94) 5.29 × 10–5 0.85 (0.79–0.92) 0.0006 0.76 (0.65–0.89)
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, P values of < 1.71 × 10–4 (0.05/292), of < 1.44 
× 10–4 (0.05/348), or of < 1.10 × 10–4 (0.05/456) were considered statistically significant in the analysis of hypertriglyceridemia, hypo–HDL-cholesterolemia, or hyper–LDL-
cholesterolemia, respectively, and are shown in bold. OR, odds ratio; CI, confidence interval; ND, not determined.
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Protein Atlas). Protein phosphatase 1 binds to regulatory 
subunits that target the enzyme to different intracellular 
locations to exert its activity toward specific substrates [35]. 
The PPP1R18 protein is a regulatory subunit that targets 
protein phosphatase 1 to the F-actin cytoskeleton [36]. 
We have now shown that rs2269704 (C/T) of PPP1R18 
was significantly associated with both the serum LDL-
cholesterol concentration and hyper–LDL-cholesterolemia, 
with the minor T allele being related to an increased serum 
LDL-cholesterol level, although the molecular mechanism 
underpinning this association is unclear.
The nurim gene (NRM) is located at chromosome 
6p21.33 (NCBI Gene) and is expressed ubiquitously 
(The Human Protein Atlas). The NRM protein contains 
transmembrane domains and resides within the inner 
nuclear membrane, where it is tightly bound to the nuclear 
envelope [37]. NRM is expressed in a broad range of 
cancers, with its expression level being correlated with 
tumor grade [38]. NRM deficiency was found to alter the 
shape of the nuclear envelope and to enhance ultraviolet 
light–induced apoptosis in HeLa cells, implicating NRM 
in suppression of apoptosis [38]. We have now shown that 
rs2269703 (G/A) of NRM was significantly associated 
with both the serum LDL-cholesterol concentration and 
hyper–LDL-cholesterolemia, with the minor A allele 
being related to an increased serum LDL-cholesterol level, 
although the molecular mechanism is unknown.
The mediator of DNA damage checkpoint 1 gene 
(MDC1) is located at chromosome 6p21.33 (NCBI 
Gene) and is expressed in various tissues and organs 
(The Human Protein Atlas). MDC1 is a nuclear protein 
required for activation of the intra–S phase and G2-M 
phase checkpoints of the cell cycle in response to DNA 
damage [39]. We have now shown that rs2269702 (A/G) 
of MDC1 was significantly associated with both the 
serum LDL-cholesterol concentration and hyper–LDL-
cholesterolemia, with the minor G allele being related to 
an increased serum LDL-cholesterol level, although the 
molecular mechanism remains unclear.
We also found that rs2853969 (C/T) at 6p21.3 and 
rs7771335 (A/G) at 6p22.1 were significantly associated 
with both the serum LDL-cholesterol concentration and 
hyper–LDL-cholesterolemia, with the minor T and G 
alleles, respectively, being related to an increased serum 
level of LDL-cholesterol. Eight SNPs (rs7771335, 
rs2071653, rs2853969, rs2269704, rs2269703, rs495089, 
rs2269702, rs1233399) associated with hyper–LDL-
cholesterolemia are all located at chromosomal region 
6p22.1-p21.3 and were in strong linkage disequilibrium.
General considerations
In previous GWASs of blood lipid traits in East 
Asian populations [24], a minor allele frequency (MAF) 
and effect size of identified SNPs were 10% to 33% and 
–0.088 to –0.050 mg/dL for triglycerides, 12% to 15% 
and –0.035 to 0.043 mg/dL for HDL-cholesterol, and 26% 
and 2.203 mg/dL for LDL-cholesterol, respectively. In 
trans-ancestry GWASs for lipid profiles [10], the MAF 
and effect size of identified SNPs ranged from 9% to 49% 
and from –0.033 to 0.037 mg/dL for triglycerides, from 
9% to 50% and from –0.051 to 0.034 mg/dL for HDL-
cholesterol, and from 4% to 48% and from –0.051 to 0.103 
mg/dL for LDL-cholesterol. In more recent GWASs that 
included low-frequency or rare variants, the MAF and 
effect size of identified SNPs ranged from 1.76% to 3.25% 
and from –30% to 21% for triglycerides, from 0.20% to 
2.01% and from –3 to 17 mg/dL for HDL-cholesterol, and 
from 0.05% to 3.43% and from –40 to 71 mg/dL for LDL-
cholesterol [11]; as well as from 1% to 47% and from 
–0.170 to 0.128 mmol/L for triglycerides, from 5% to 20% 
and from –0.141 to 0.044 mmol/L for HDL-cholesterol, 
and from 1% to 21.6% and from –0.049 to 0.648 mmol/L 
for LDL-cholesterol, respectively [12]. Studies based on 
exome and whole-genome sequencing identified SNPs 
with a MAF and effect size from 0.06% to 28.2% and from 
–98.0 to 51.5 mg/dL, respectively, for LDL-cholesterol 
[13]; as well as those with a MAF of 0.007% to 4.6% and 
effect size of –65.3 to 12.0% for triglycerides and –0.087 
to 0.40 mmol/L for HDL-cholesterol [14].
In our study, among 46 SNPs associated with the 
serum triglyceride concentration, one SNP was a rare 
variant (MAF, 0.3%) with a large effect size (difference 
in serum triglyceride level among genotypes, 28.1%), 
eight SNPs were low-frequency variants (1.2–3.3%) with 
a moderate to large effect size (14.6–19.8%), and 37 SNPs 
were common variants (7.3–47.6%) with a small to large 
effect size (6.2–45.2%) (Supplementary Table 19). Among 
104 SNPs associated with the serum HDL-cholesterol 
concentration, nine SNPs were rare variants (MAF, 
0.2–0.3%) with a large effect size (difference in serum 
HDL-cholesterol level among genotypes, 17.3–29.3%), 
32 SNPs were low-frequency variants (0.5–4.5%) with a 
moderate to large effect size (5.2–25.8%), and 63 SNPs 
were common variants (5.0–47.6%) with a small to large 
effect size (3.3–18.7%) (Supplementary Table 20). Among 
40 SNPs associated with the serum LDL-cholesterol 
concentration, three SNPs were low-frequency variants 
(MAF, 1.1–4.3%) with a large effect size (difference 
in serum LDL-cholesterol level among genotypes, 
16.8–24.8%) and 37 SNPs were common variants (6.6–
27.9%) with a small to moderate effect size (2.8–9.2%) 
(Supplementary Table 21).
Study limitations
There are several limitations to the present study. (1) 
Our results were not replicated and will therefore require 
validation in independent subject panels or in other ethnic 
groups. (2) Subjects who had treatment for other diseases 
such as diabetes mellitus were included in the study. It 
was possible that such treatment affected lipid profiles 
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of the subjects. (3) SNPs identified in our study might 
be in linkage disequilibrium with other polymorphisms 
in the nearby genes that are actually responsible for the 
observed associations. (4) Three SNPs associated with 
hyper–LDL-cholesterolemia were not significantly related 
to the serum LDL-cholesterol concentration, which may 
be attributable to the effects of medical treatment. (5) The 
functional relevance of the observed associations remains 
to be determined.
MATERIALS AND METHODS
Study subjects
A total of 14,337 subjects (8354 individuals with 
dyslipidemia, 5983 controls) was recruited as described 
previously [40].
Venous blood was collected in the early morning 
after the subjects had fasted overnight. Blood samples were 
centrifuged at 1600 × g for 15 min at 4°C, and serum was 
separated for subsequent analysis. Serum concentrations 
of triglycerides, HDL-cholesterol, and LDL-cholesterol 
were measured at the clinical laboratory of each hospital. 
The 4742 subjects with hypertriglyceridemia and 8672 
controls had serum triglyceride concentrations of ≥ 
1.69 mmol/L (range, 1.69 to 20.14 mmol/L) and < 1.69 
mmol/L (0.14 to 1.68 mmol/L), respectively; the 2646 
subjects with hypo–HDL-cholesterolemia and 11,473 
controls had serum HDL-cholesterol concentrations of < 
1.03 mmol/L (0.26 to 1.01 mmol/L) and ≥1.03 mmol/L 
(1.03 to 4.73 mmol/L), respectively; and the 4489 subjects 
with hyper–LDL-cholesterolemia and 9088 controls had 
serum LDL-cholesterol concentrations of ≥ 3.62 mmol/L 
(3.62 to 12.31 mmol/L) and < 3.62 mmol/L (0.26 to 3.59 
mmol/L), respectively. Individuals with dyslipidemia 
had at least one of hypertriglyceridemia, hypo–HDL-
cholesterolemia, and hyper–LDL-cholesterolemia, or 
were taking anti-dyslidemic medications. The 1300 
subjects with both hypertriglyceridemia and hypo–HDL-
cholesterolemia as well as 7844 controls overlapped 
between the corresponding studies, as did the 2002 
subjects with both hypertriglyceridemia and hyper–
LDL-cholesterolemia and 6326 controls as well as the 
712 subjects with both hypo–HDL-cholesterolemia 
and hyper–LDL-cholesterolemia and 7776 controls. 
Individuals with single-gene disorders such as familial 
hypercholesterolemia or with endocrinologic or metabolic 
diseases that cause dyslipidemia were excluded from the 
study. Those taking medications that may cause secondary 
dyslipidemia were also excluded. Autopsy cases were 
excluded from controls.
The study protocol complied with the Declaration 
of Helsinki and was approved by the Committees on the 
Ethics of Human Research of Mie University Graduate 
School of Medicine, Tokyo Metropolitan Institute of 
Gerontology, Hirosaki University Graduate School of 
Medicine, and participating hospitals. Written informed 
consent was obtained from each participant or families of 
the deceased subjects.
EWASs
Methods for collection and extraction of genomic 
DNA samples were described previously [40]. EWASs for 
the serum concentrations of triglycerides (13,414 subjects), 
HDL-cholesterol (14,119 subjects), or LDL-cholesterol 
(13,577 subjects) or for hypertriglyceridemia (4742 
cases, 8672 controls), hypo–HDL-cholesterolemia (2646 
cases, 11,473 controls), or hyper-LDL-cholesterolemia 
(4489 cases, 9088 controls) were performed with 
HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or 
Infinium Exome-24 v1.0 BeadChip arrays (Illumina, San 
Diego, CA). Detailed information of the exome arrays and 
methods of quality control were described previously [40]. 
Totals of 41,371, 41,225, and 41,347 SNPs passed quality 
control in the EWASs for hypertriglyceridemia, hypo–
HDL-cholesterolemia, and hyper–LDL-cholesterolemia, 
respectively, and were included in the analysis.
Statistical analysis
The relation of SNP genotypes to the serum 
concentrations of triglycerides, HDL-cholesterol, or 
LDL-cholesterol in the EWASs was examined with linear 
regression analysis. For analysis of characteristics of the 
study subjects, quantitative and categorical data were 
compared between cases and controls with the unpaired 
Student’s t test and Fisher’s exact test, respectively. Allele 
frequencies were estimated by the gene counting method, 
and departure from Hardy-Weinberg equilibrium was 
identified with Fisher’s exact test. The relation of allele 
frequencies of SNPs to hypertriglyceridemia, hypo–
HDL-cholesterolemia, or hyper–LDL-cholesterolemia 
in the EWASs was examined with Fisher’s exact test. To 
compensate for multiple comparisons of genotypes or allele 
frequencies with lipid concentrations or dyslipidemia, we 
applied Bonferroni’s correction for statistical significance 
of association. Given that 41,225 to 41,371 SNPs were 
analyzed, a P value of < 1.21 × 10–6 [0.05/(41,225 to 
41,371] was considered statistically significant for 
the EWASs. Quantile-quantile plots for P values of 
genotypes or allele frequencies in the EWASs are shown in 
Supplementary Figures 3 and 4, respectively. The inflation 
factor (λ) was 1.05 for serum triglycerides, 0.97 for 
serum HDL-cholesterol, 1.06 for serum LDL-cholesterol, 
1.20 for hypertriglyceridemia, 1.29 for hypo–HDL-
cholesterolemia, and 1.20 for hyper–LDL-cholesterolemia. 
Multivariable logistic regression analysis was performed 
with hypertriglyceridemia, hypo–HDL-cholesterolemia, 
or hyper–LDL-cholesterolemia as a dependent variable 
and independent variables including age, sex (0, woman; 
1, man), and genotype of each SNP. A detailed method 
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of analysis was described previously [40]. Relations of 
genotypes of identified SNPs to serum concentrations of 
triglycerides, HDL-cholesterol, or LDL-cholesterol were 
examined by one-way analysis of variance. Bonferroni’s 
correction was also applied to other statistical analysis 
as indicated. Statistical tests were performed with JMP 
Genomics version 6.0 software (SAS Institute, Cary, NC).
CONCLUSIONS
The SNPs rs146515657 of USP4 and rs147317864 
of TRABD2B may be novel determinants of hypo–HDL-
cholesterolemia whereas rs2853969 at 6p21.3, rs7771335 
at 6p22.1, rs2071653 of MOG, rs2269704 of PPP1R18, 
rs2269703 of NRM, and rs2269702 of MDC1 may be new 
determinants of hyper–LDL-cholesterolemia. In addition, 
12, 61, 23, or 3 SNPs may be new determinants of the 
serum triglyceride, HDL-cholesterol, or LDL-cholesterol 
concentrations or of hyper–LDL-cholesterolemia, 
respectively. Determination of genotypes for these SNPs 
may prove informative for assessment of the genetic risk 
for dyslipidemia in Japanese.
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